BioSpace News Archive

Clinical Experience with Penumbra JET™ 7 Reperfusion Catheter with XTRA FLEX Technology to be Highlighted at Company-Sponsored Symposium

Exicure, Inc., a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced its appointment of Jeffrey L. Cleland, Ph.D. and Timothy P. Walbert to its Board of Directors.

Novartis is teaming up with celebrity interior designer Nate Berkus to launch My Home in Sight, a program that aims to raise awareness of the daily impact of wet age-related macular degeneration and empower those living with wet AMD and their caregivers to make simple, functional changes to support safety and independence at home.

Biohaven Pharmaceutical Holding Company Ltd. announced that enrollment in the T2 Protect AD Study, a Phase 2/3 clinical trial of troriluzole in Alzheimer’s disease, is progressing on timelines with more than 400 subjects enrolled and over 180 subjects randomized to study treatment.

Provide superior ferromagnetic item detection to strengthen MRI safety screening programs.

TIDI Products, LLC, a leading provider of medical technology solutions including Sterile-Z®, C-Armor®, TIDIShield®, and Posey®, announced the addition of PenBlade®, a single-use safety scalpel, to its portfolio of acute care consumables focused on surgical solutions.

DURECT Corporation (Nasdaq: DRRX) announced today that it has entered into an agreement with Gilead Sciences, Inc. granting Gilead the exclusive worldwide rights to develop and commercialize a long-acting injectable HIV product utilizing DURECT’s SABER® technology

Wireless Cardiac Pacing System being evaluated in global clinical study for Heart Failure Patients

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved the inclusion of overall survival (OS) data from the Phase III PACIFIC trial in an update to the IMFINZI®

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the VX-445 (elexacaftor), tezacaftor and ivacaftor triple combination regimen